A clinical trial update for survodutide was recorded on August 21, 2026. The study, registered as NCT06632457 and titled "LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis," is a Phase 3 trial. Its current status is listed as recruiting.
According to the registry, the trial is designed to test survodutide in people with NASH/MASH who also have cirrhosis. No results have been posted for this trial as of this update. The status reflects only that recruitment is ongoing, not any outcome or effect of the compound.
Survodutide remains classified as an unapproved compound under research and is not approved for use outside of clinical trial settings. This update reports only the trial's registered status, phase, and title as listed on ClinicalTrials.gov. It does not indicate safety or efficacy findings.
Readers interested in learning more about survodutide, including its research background and mechanism, can consult the compound overview for additional context.